Try our Advanced Search for more refined results
Life Sciences - March, 2023
345 articles
- J&J Can't Keep Talc Ch. 11 During High Court Appeal
- 7th Circ. Kicks Back Illustration Infringement Case, Again
- Roundup Buyer Attys Get $5.75M In Fees In False Ad Case
- Doctor's Patent App Survives PTAB's 2nd Derivation Ruling
- Surescripts Holds Monopoly In E-Prescriptions, Judge Says
- AmerisourceBergen Seeks Toss Of DOJ's Opioid Suit
- 4 Potential Paths For High Court In Amgen Patent Case
- Fed. Circ. Upholds ITC Ban On Philip Morris IQOS Devices
- Don't Miss It: Latham, Crone Law Lead Week's Hot Deals
- Biotech Firms Pursue Alternatives While IPOs Remain Cold
- Jury Says Sandoz Owes $39M For Eyelash Drug Infringement
- Ky. Gov. Signs Bill To Legalize Medical Cannabis
- SEC Keeps Heat On Cos. Seeking To Bar Investor Proposals
- NJ Man Wants No Jail Time In Pandion Insider Trading Case
- Patent Suit Over Generic IBS Drugs Will Go On
- Surgeon Loses Bid For Tripled Damages In Patent Case
- EU Official Questions Criticism Of EU, US Enforcers Talking
- Ex-CEO Whistleblower Nets $12M In Hospital's $69M FCA Deal
- Pesticide Maker Backs Monsanto In 11th Circ. Roundup Redo
- Manufacturer Skirts Death Claims Over Stuck Car Seat Buckle
- Fox Ex-Producer Case Is A Lesson In Joint Representation
- Cannabis Cos. Must Heed Growing Federal Investigatory Risks
- Chemical Cos. Want To Keep 2 Asbestos Suits Separate
- Hearing Loss Biotech Escapes Investors' Stock Suit
- SG Sides With Teva In High Court Skinny Label Patent Case
- ITC Confronts Divergent Views On Expanding COVID IP Deal
- Outcome's Problems Came From 'Fraud Island,' Jury Hears
- 11th Circ. Tosses Fla. Attorney's Mask Mandate Suit
- Biogen Judge Tosses Investor Suit, Calling It 'House Of Cards'
- Chancery Flat-Lines Bid To Stop Heart Valve Co. Patent Sale
- Biotech Co. Codiak Plans Ch. 11 Sale Of Lab, IP Assets
- 3rd Circ. Orders Trial In Pharma Fraud Coverage Suit
- McKesson Beats Oncology Kickback Whistleblower Suit
- Delaware High Court Skeptical Of State's Monsanto PCB Suit
- Walmart Can't Nix 'Maximum Strength' Lidocaine False Ad Suit
- Ex-Compliance Chief Who Aided Feds In Oxy Case Avoids Jail
- A Tale Of 2 State Tax Sourcing Decisions: The Pa. Court's Path
- Illumina Investor Loses Insider Trading Appeal In 2nd Circ.
- 6th Circ. Widens FCA Split, Curtails Kickback Law's Scope
- FTC Calls Juul-Altria Settlement Offer 'Woefully Short'
- Whistleblower Grafting Old Claim On New Suit, Skin Co. Says
- Biz Groups Ask High Court To Use 'Objective' FCA Standard
- Allergan Drops Willfulness Allegation In Eyelash Drug Suit
- 'Fake It Till You Make It' Was The Outcome Way, Jury Hears
- Apple Can Call CEO For Rebuttal In Trade Secrets Trial
- Heart Device Maker Tells Del. Court: Patents Already Sold
- 2nd Circ. Backs Toss Of FCA Case Involving Cancer Group
- Justices Question Post-Dobbs Bar On Georgia Abortion Law
- Recent Growth Factors Driving Life Sciences Transactions
- A Tale Of 2 State Tax Sourcing Decisions: The Va. Court's Path
- Insights After High Court Arguments In Amgen Patent Case
- Vanda Can See FDA Docs On Drug Label Denial, Judge Says
- Stanford Law Protest Highlights Rise Of Incivility In Discourse
- 50 Cent Settles False Advertising Suit With Fla. Medical Spa
- Holland & Knight Adds K&L Gates Tech Policy Team In DC
- DOJ Fights Pharma Exec's Bid To Delay Price-Fixing Trial
- Outcome Ex-Growth Chief Says He Didn't 'Corrupt' Workers
- Novartis Co. 'Jumped The Gun' With Eyelash Drug, Jury Told
- 7th Circ. Revives Ill. Student's Pandemic Tuition Refund Suit
- Texas Attys. Can't Lead Class In Abortion Row, Judge Told
- Court Eyes Attorney Actions In 'Sham' Androgel Patent Suit
- Justices Experiment With Enablement Paths In Amgen IP Row
- Kansas Supreme Court Skeptical Of Laws Restricting Abortion
- How Kickbacks Became King In False Claims Act Litigation
- Ohio AG Says Pharmacy Middlemen Colluded To Hike Prices
- Milwaukee Industry Park's Ex-Owner Liable For Cleanup
- Wholesaler To Pay $33.4M In Abbott Labs Test Strips TM Row
- Cardiac Implant Maker Sued In Del. Over Snubbed Offer
- $490M FCA Award Unconstitutional, Distributor Insists
- Psychedelics Policy Roundup: RI Sens. Pitch Psilocybin Bill
- Sorrento Therapeutics Agrees To Shareholder Committee
- Consumers Contest Abbott's Bid To Toss Infant Formula MDL
- No Emotional Damages For Loss Of Pets, Mich. Panel Rules
- Dispute Prevention Strategies To Halt Strife Before It Starts
- Catching Up With Delaware's Chancery Court
- Dormant Commerce Clause Issues Are Evolving In Cannabis
- Federal Judge Downs 'Rapid Release' Tylenol Suit
- Biotech Firm Codiak BioSciences Hits Ch. 11 With Sale Plan
- Opioid Theory Reaches 'Alcohol, Guns, Phones,' 4th Circ. Told
- Amgen Supreme Court Arguments Aren't Just About Biology
- Drugmaker Not Defamed By Medical Journal, 3rd Circ. Rules
- Bystolic 'Side Deals' Deemed Legit, Not Generic Delay Plans
- Monster's $167M Additional Relief Bid 'Falls Short,' VPX Says
- NH High Court Nixes Med. Monitoring In PFAS Class Action
- Minn. Attorney General Discusses Juul, First E-Cigarette Trial
- CR Bard Defeats Counterclaims In $27M Surgical IP Row
- Tricida Heading For Ch. 11 Confirmation Fight With Creditors
- NYPD Can't Dodge Suit Over Expansive DNA Database
- Icahn Calls Illumina's Grail Move 'A New Low' Amid Proxy War
- Ex-Dialysis Co. Execs Can't Dodge SEC Accounting Fraud Suit
- BetterHelp Hit Again With Class Action Over Data Protection
- UK Litigation Roundup: Here's What You Missed In London
- Health Hires: Gordon & Rees, Axogen, Capstan
- Attys Get $18.8M In Allergan, Merz 'Pay-For-Delay' Settlement
- Denial Of Xtandi March-In Rights Petition Appealed To HHS
- 5th Circ. Halts FDA Ban On RJ Reynolds Menthol Vapes
- Boston Scientific Says University 'Poisoned' $42M Patent Trial
- FTC Blasts Illumina's 'Conspiracy Theory' Over Grail Deal
- IP Forecast: BMW Looks To Toss Patent Suit, Seeks Sanctions
- Medical Software Co. Sued After 2nd Data Breach In 4 Years
- Would-Be Ark. Pot Seller Loses Suit Over Licensing Process
- What To Know Before Justices Take On Patent Enablement
- Masimo Unveils Board Changes Amid Politan Suit In Delaware
- Gerber Wants Class Decertified In Formula False Ad Suit
- Defamation Alternatives For Suing Hoax Social Media Users
- Practical Skills Young Attorneys Must Master To Be Happier
- Ex-Aegerion Rep Can't Nix Fraud Counts Over Edit, Feds Say
- Deals Rumor Mill: Commanders, FTX, Baxter International
- New Mich. Cannabis Policy May Lower Costs For Some Cos.
- Wyoming Judge Blocks State's Abortion Ban, For Now
- Aquavit Scores $10M Win In Aquagold TM Fight Against Rivals
- Feds Tell 6th Circ. Pharmacies Have Opioid Duties
- No Dispute Gilead HIV Drug Causes Injuries, Patients Say
- Spain Touts Highest Female Inventors Rate, US Trails Behind
- Chancery Won't Redo AmerisourceBergen Opioid Suit
- Sanofi Tells Justices It Couldn't Give Away EpiPen Rival
- Moderna Exec Stands By COVID-19 Vaccine Price Increase
- Amarin Asks Fed. Circ. To Undo Heart Drug IP Decision
- McDermott Lands Deals Attys From Pillsbury, Gibson Dunn
- J&J Plans High Court Appeal After 3rd Circ. Tosses Talc Ch. 11
- Could The Supreme Court Legalize Marijuana Federally?
- DC Circ. Backs Dismissal Of Navy Worker's Vax Mandate Suit
- Rite Aid Hit With Investor Suit Over DOJ Opioid Action
- Okla. Justices OK Abortions That Preserve Women's Lives
- NIH Won't Seize Patents To Cut Price Of Cancer Drug Xtandi
- High Court Urged To Back Objective FCA Knowledge Standard
- Freezer Co. Says Supplier Must Chip In On $15M Embryo Loss
- AbbVie Inks $2.7M Deal To End Humira FCA Kickback Battle
- DOJ Vowed 'Difficult Cases.' It Still Bowed To UnitedHealth
- Okla. Cancels First Pot License Over 'Ghost Ownership'
- Amgen Must Face Regeneron's Bundling Antitrust Suit
- Treasury Clarifies Eligibility For Chips Tax Credit
- GW Pharma Investors Ink $7.75M Deal In Suit Over Jazz Sale
- Citadel Securities, Others Want Biotech Spoofing Suit Nixed
- FTC Warns Of Harm In Generic Parkinson's Drug Antitrust Suit
- Stimwave Secures Ch. 11 Plan Confirmation In Delaware
- Glancy Prongay Drops Out Of Blood Drug Lead Counsel Race
- 3rd Circ. Skeptical Vaccine Refusal A 'Fundamental Right'
- Pennsylvania Is Gathering Momentum On Adult-Use Cannabis
- Fed. Circ. Urged To Upend Actavis' $12M Legal Fee Deduction
- Cannabis REIT Hit With Shareholder Derivative Action
- NantCell Kicked Off Creditor Committee In Sorrento Ch. 11
- Colorado Biopharma Co. Settles Stock Split, Share Award Suit
- DOJ Quietly Abandons UnitedHealth Merger Appeal
- Idaho Hospital To Stop Delivering Babies Amid Legal Dilemma
- FDA Urges Court To Keep Abortion Drug Regulations Intact
- High Court Tosses Immunity Ruling In Missouri Abortion Fight
- Justices Let Gov't Join FCA Scienter Args, Balk At Extra Time
- HHS Advisory Opinion Serves As Free Drug Program Guide
- DOJ Defends Ask For Docs From Drug Price-Fixing MDL
- Illumina Says Icahn Nominees Would 'Damage' Core Business
- 50 Years In, Industry Has Knives Out For Potent Kickback Law
- Sorrento Shareholders Say They Need Committee In Ch. 11
- Feds Want $490M Award After FCA Kickback Verdict
- Holmes Restitution Hearing Draws Autograph-Seekers
- Court Backs $125M Sorrento Cancer Drug Arbitration Win
- Startup Targets 'Purged' Emails In Suit Against Apple
- Olly Wants Excess Melatonin Suit Trimmed
- SVB's Fall Portends Even Leaner Times For Private Startups
- Ex-Biotech Exec Ordered To Pay $45K Over Fraud Allegations
- FTC Urges DC Circ. Not To Prolong Endo-Impax Monopoly
- Bipartisan Reps. Introduce Bills To Regulate CBD Products
- ABA Opinion Should Help Clarify Which Ethics Rules Apply
- Merck, Viatris Settle Diabetes Drug Patent Fight After Appeal
- Balwani Snags Last-Minute Prison Reprieve With Fresh Appeal
- ND Supreme Court Finds Abortion Ban Likely Unconstitutional
- DOJ Asks USPTO To Look At Anti-Competitive Patent Abuse
- Surescripts, FTC 'Ought To Be Talking Again,' Judge Says
- Cell Research Co. Strikes Deal To End Clinical Data Suit
- Curtailing Offshore Tax-Advantaged Investment In China
- 6th Circ. Pans 'Shocking Lack Of Evidence' In Med Mal Suit
- J&J Ordered To Pay $40M In Damages In Antitrust Suit
- Monsanto Asks 11th Circ. To Bar Doctor's Roundup Claims
- NJ Panel Says Suit Isn't Coherent Enough To Fully Dismiss
- J&J And Ethicon Score Pelvic Mesh Trial Win In Fla.
- 4 Ways To Reboot Your Firm's Stalled Diversity Program
- Families In GSK MDL Rip Shook Hardy For 'Ironic' Costs Bid
- Texas Judge Challenges Claim Abortion Pill Suit Filed Too Late
- SEC Axes Eli Lilly Bid To Duck Diversity, Abortion Reports
- Pharma Co. Gets Investor Suit Over New Diazepam Drug Axed
- Why Holmes Is Unlikely To Avoid Prison While She Appeals
- Driver Says Pharmacy, Courier Co. Don't Pay Minimum Wage
- Bank Failures Shine Light On Corporate Governance Risks
- Biz Court Ignored Deception In Fraud Suit, NC Justices Hear
- Icahn Says Illumina Stance 'Insulting' As Proxy War Brews
- Judge Refuses To Split Upcoming Zetia Antitrust Trial
- DOJ's Google Sanctions Motion Shows Risks Of Auto-Deletion
- Janssen Says Whistleblower FCA Claim Already Disclosed
- J&J MDL Atty Joins Barnes & Thornburg's Windy City Office
- PE-Backed Biz Interrupts $425M Merger Of Biotech Firms
- Amgen Hid IRS' $10B Tax Dispute, Shareholder Suit Alleges
- Calbiotech Urges Rejection Of Ex-Worker's Sanctions Bid
- Roche Blasts Attys' 'Misconduct' In Diabetes Fraud Deposition
- Ohio's GOP Justices Vote To Review Block On Abortion Ban
- Pharma Co. Says Rival Stole Psychedelic Treatment Formula
- Fed. Circ. Unsure Vanda's Sleep Med Hetlioz Is Patentable
- CVS Tells 9th Circ. Choctaw's Claims Must Be Arbitrated
- Mich. Seeks Murder Verdict Over Moldy Drugs After Feds Fail
- Mylan Execs Were Unaware Of W.Va. Plant Issues, Court Told
- To Fight Consumer Hair Loss Claims, Focus On Causation
- What To Expect From A Litigation Finance Industry Recession
- OKYO Pharma Eyes Raising $5.74M From Share Placing
- Apollo Funds Taking Univar Solutions Private In $8.1B Deal
- CVS Can't Escape FCA Suit Alleging Drugmaker Collusion
- Pharma Cos. Say Civil Evidence Off Limits In Criminal Case
- Surescripts Says Loyalty Programs' End Moots FTC Case
- How Public Companies Are Responding To SVB's Collapse
- J&J Wants Rival's 'Meritless Delay Tactic' Denied
- Fintiv Challenge Rolls On, But Odds Of Sinking Rule Dwindle
- Allergan Gets FCA Suit Tossed On Remand From 9th Circ.
- Feds Say Rite Aid Ignored 'Red Flags' On Opioid Prescriptions
- Texas Sees 1st Suit Alleging Aborted Fetus' Wrongful Death
- Judge Goes Public With Abortion Hearing Info After Outcry
- Recent Trends In Multiple First Generic Drug Filings
- Pierre Fabre Benzene Shampoo Suit Not A Wash, Court Told
- 2nd Circ. Won't Undo Colgate's $300M Loss In ERISA Suit
- Law Groups Tell Full 11th Circ. Roundup Claims Negate EPA
- 3rd Circ. Grants Amicus Bids Of Profs, Ex-Judge In LTL Case
- 2 Firms Lead Sanofi's Provention Bio Buy Worth $2.9B
- Illumina Hit With Proxy Contest By Activist Investor Carl Icahn
- J&J Unit Ch. 11 Case Shows Texas 2-Step May Be Wrong Move
- Fed. Circ. Revives Tech Giants' Suit Targeting Fintiv
- Pfizer Buys Seagen In $43B Enterprise Value Deal
- Altria Fights Telling Jury About Juul Settling Vaping Claims
- Judge Not Convinced By DOJ's 'Say-So' In Vax IP Row
- Calif. Appeal Panel Affirms Ax Of Zantac Prop 65 Claims
- Ethicon And J&J Snag 4th Circ. Win In Pelvic Mesh Appeal
- HPV Suit Not Covered By Geico Auto Policy, Judge Says
- CORRECTED: 'A Huge Waste Of Time': Judge Gives Allen & Overy Atty Earful
- Lawmakers Urge Transparency In Federal Pot Reevaluation
- FCA Knowledge Element: NY Already Got It Right
- Generic Drug Buyers Get $75M In Price-Fixing Deals Approved
- UK Litigation Roundup: Here's What You Missed In London
- Breaking Down Maryland's Adult-Use Cannabis Bill
- Janssen Must Hand Over Records In Kickback Case
- Taxation With Representation: Gibson Dunn, Wachtell, Davis
- UK Teva Ruling Brings Patent Remedy Into Question
- Family Sues Fla. Airbnb Over Baby's Fentanyl Death
- Foreign Tech Bill Hones Commerce's Growing Nat. Sec. Role
- Mylan Asks Supreme Court To Deny Sanofi's EpiPen Bid
- Stimwave Pays $10M To Avoid Prosecution; Ex-CEO Charged
- Family Sues Over ICE Detainee's COVID-19 Death
- CBD Co. Can't Avoid Counterclaims In Trademark Dispute
- FDA Calls For Better Baby Formula Safety Practices
- Cannabis And Psychedelics Roundup: Sens. Eye More Studies
- Teva Wants Out of Case Targeting Blockbuster MS Drug
- HHS Budget Highlights Insulin Costs, Family Planning
- FDA Seeks $7.2B In 2024 Budget, Highlighting Food Safety
- Altria To FTC: There's No More Juul Investment To Challenge
- Gas Facility Opponents Say FERC Didn't Weigh Health Impacts
- House Panel Focuses On Expanding JOBS Act Benefits
- Regeneron Ignoring FCA Law 'Common Sense,' Feds Say
- Mintz Debuts 'Femtech' Practice For Life Science Clients
- Moderna Tries To Kick Ex-Judge Out Of COVID Vax IP Row
- AmEx Could Face Shareholder Vote On Abortion Ban Risks
- Anti-Abortion Group To Take Free Speech Fight To High Court
- Illumina Says EU Comms Underscore FTC Bias Over Grail
- Judge Says Ipsen IP Row Belongs In Belgium
- Opioid Judge Eyes New Bellwethers Amid 'Unwieldy' Delays
- Gilead Wins $131M From Fla. Clinics Over HIV Meds Scam
- Zetia Buyers Face Tough Road For Bid To Split Up Trial
- DC Judge Axes Medical Device Group's Copyright Office Suit
- FDA Proposes New Tobacco, E-Cig Manufacturing Rule
- 3 Firms Face Off For Lead Counsel Spot In Blood Drug Suit
- Ex-CEO Convicted In Landmark Opioid Case Gets 27 Months
- Solenis To Buy Diversey In $4.6B PE-Backed, Go-Private Deal
- 'Clear Quid Pro Quo': HHS Jeers Big Pharma's Kickback Salvo
- Talc Claimants Rip J&J Unit's Bid For Full 3rd Circ. Rehearing
- Amgen Says Sanofi Contradicting Itself In High Court IP Feud
- Women Denied Abortions In Medical Emergencies Sue Texas
- DEA's Proposed Telehealth Rules May Be Too Restrictive
- Ohio Nurse Says Hospital Failed To Pay Required OT Wages
- CVS Beats NY AG Drug Subsidy Tying Suit, For Now
- Walgreens Seeks Quick Exit in Kids' Cough Medicine Suit
- Hedge Fund Manager Priest Denied Rehearing From 1st Circ.
- Cozen O'Connor Launches Data Privacy Practice In Chicago
- 10th Circ. Ruling Shows Hemp Issues Need Congressional Fix
- DOJ Cautions Execs With Novel Insider Trading Case
- 9th Circ. Doubts FTC's Industry Ban For COVID PPE Delays
- Merck Hit With 3rd-Party Payor Suit Over Vaccine Bundling
- Fed. Circ. Squints To Find Wrinkle Treatment Differences
- Pharma Co. Wants Suit Over Underpaying Board Chair Axed
- ITC Judge Details Why Cannabis Cos. Beat IP Investigation
- $54M Wolverine, 3M PFAS Settlement Nears Final Approval
- Gilead Prevails In Antiviral IP Claim Fight At Fed. Circ.
- Retired Judge, Profs Oppose J&J Unit's Chapter 11 Bid
- Tricida Heads To Ch. 11 Mediation Over Creditor Plan Issues
- DuPont Hit With Pension Benefit Miscalculation Suit
- Tribes And Others Fight To Keep McKinsey Opioid Suit Alive
- Justices Leave Questions Open On Dual-Purpose Atty Advice
- Michigan's New Abortion Rights May Crush Old Legal Barriers
- Nixon Peabody Expands Complex Disputes Practice In NY
- COVID Test Co. Will Pay $500K To End SEC Fraud Claims
- Justices Won't Hear Ex-Abbott Worker's Race Bias Appeal
- Elizabeth Holmes Fights 'Sweeping' $900M Restitution Bid
- Ex-Judges Worried About Where COVID Vax IP Row Will Go
- Hain Gets Midtrial Win On Claim Baby Food Caused Autism
- 11th Circ. Agrees Ala. Pharmacist's COVID Suit Is State Matter
- MacroGenics Beats Cancer Drug Securities Suit At 4th Circ.
- Precigen Strikes $13M Deal In Investors' Gas Fraud Suit
- Investors' COVID Vax Suit Against Drugmaker Tossed
- Gov't Doesn't Owe Cotter Indemnity For Radiation Injury Suit
- Amgen, Teva Want Another Shot At Quick Sensipar Appeal
- An Update On The Eliminating Kickbacks In Recovery Act
- HEC Says Axed Novartis Patent Win 'Not Remotely Certworthy'
- Nurses And Doctor Face Fines Over False COVID-19 Claims
- Co-Counsel Named In L'Oreal Hair Relaxer MDL
- Health Hires: McDermott, Gordon Rees
- Trending At The PTAB: Fintiv Is Alive, But With Way Less Zip
- Life Sciences Group Of The Year: Covington
- UK Litigation Roundup: Here's What You Missed In London
- Cannabis And Psychedelics Roundup: A Caucus Reintroduced
- J&J Page-Limit Flub Stifles Amgen Injunction, For Now
- Fertility Clinic 'Doomed' Baby To Stomach Removal, Suit Says
- Catalyst Launches Patent Suits Over Drug Firdapse
- IP Forecast: Atty's TM Fraud Fight Makes Its Way To Fed. Circ.
- Worry Over Abortion Info Access Spurs Call For Net Neutrality
- CBD Pharma Co. Sues Beverage Co. Over $25M Sale Deal
- FCA Enforcement And Litigation Trends To Watch
- Antitrust Suit Against Amarin Pharma Forges Ahead
- Ex-Pharmacy Tech's FMLA Firing Suit Heads To Trial
- Eli Lilly Says 'Vitriol' Behind Teva's Bid To Triple IP Verdict
- Butzel Long Adds Veteran Gov't Relations Atty In DC
- Judge Criticized By Medical Device Co. Tosses Its Retrial Bid
- Members In $8M Class Action Got Bad Deal, 11th Circ. Told
- Feds Want 15 Years For Former CEO In Landmark Opioid Case
- Bill Would Close Patent 'Loophole' Used To Block Generics
- Absent Federal Action, Tribal Cannabis Laws Remain In Limbo
- Life Sciences Group Of The Year: Arnold & Porter
- Deals Rumor Mill: Pfizer, Altria, Stripe
- As Opioid Sellers Win Vital Verdict, Families See Silver Lining
- Biogen Owes Patent Royalties For MS Drug, Genentech Says
- Bristol-Myers Slips Suit Over $6.4B Investor Payment, For Now
- Judge Trims Retailer's TM Suit Over Celebrity Laser Treatment
- Calif. Co. Files Patent Suits Over Pot Extraction Technologies
- Some Zetia Buyers No Longer Want Split Trial
- Michigan Cases To Watch In 2023
- Garland Defends DOJ Steps On Justices' Safety, Major Probes
- Patients Sue Med Group Over Delayed Response To Hack
- DOJ Fraud Section's 2022 By The Numbers
- Class Cert. Denied Again In Gout Drug Antitrust Case
- J&J Ch. 11 Dismissal Ignores Mass Tort Bankruptcy Principles
- Distributors Win Milestone Trial Over Individual Opioid Abuse
- ITC 100-Day Early Disposition: Little Used But Top Of Mind
- Life Sciences Group Of The Year: Quinn Emanuel